Drugs for Neglected Diseases Initiative donations received

This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of December 2019. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.

Table of contents

Basic donee information

ItemValue
Country
Facebook page dndi.org
Websitehttps://www.dndi.org/
Twitter usernameDNDi
Wikipedia pagehttps://en.wikipedia.org/wiki/Drugs_for_Neglected_Diseases_Initiative
Instagram usernamedrugsforneglecteddiseases

Donee donation statistics

Cause areaCountMedianMeanMinimum10th percentile 20th percentile 30th percentile 40th percentile 50th percentile 60th percentile 70th percentile 80th percentile 90th percentile Maximum
Overall 18 1,868,635 7,345,315 -1,522,143 -1,335,450 53,058 1,000,000 1,713,553 1,868,635 2,352,649 4,802,610 9,000,000 25,729,284 59,867,584
Global health 15 2,352,649 8,572,029 -1,522,143 -1,335,450 -540,152 1,000,000 1,500,000 2,352,649 4,398,239 5,787,659 9,000,000 25,729,284 59,867,584
FIXME 3 1,713,553 1,211,749 53,058 53,058 53,058 53,058 1,713,553 1,713,553 1,713,553 1,868,635 1,868,635 1,868,635 1,868,635

Donation amounts by donor and year for donee Drugs for Neglected Diseases Initiative

Donor Total 2017 2015 2014 2013 2011 2010 2009 2007
Bill and Melinda Gates Foundation (filter this donee) 128,580,432.00 4,802,610.00 -1,335,450.00 63,743,680.00 2,352,649.00 16,787,659.00 1,500,000.00 15,000,000.00 25,729,284.00
Wellcome Trust (filter this donee) 3,635,246.00 0.00 0.00 0.00 53,058.00 3,582,188.00 0.00 0.00 0.00
Total 132,215,678.00 4,802,610.00 -1,335,450.00 63,743,680.00 2,405,707.00 20,369,847.00 1,500,000.00 15,000,000.00 25,729,284.00

Full list of documents in reverse chronological order (1 documents)

Title (URL linked)Publication dateAuthorPublisherAffected donorsAffected doneesDocument scopeCause areaNotes
Sindy li: current view, Against Malaria Foundation2017-02-19Sindy Li Oxford Prioritisation ProjectOxford Prioritisation Project Against Malaria Foundation Schistosomiasis Control Initiative Drugs for Neglected Diseases Initiative Evaluator review of doneeGlobal healthSindy Li provides her best guess as to the best opportunity for the Oxford Prioritisation Project, saying it is the Against Malaria Foundation. Her analysis relies on the GiveWell cost-effectiveness estimates. She identifies mental health as another area (citing https://oxpr.io/blog/2017/2/28/lovisa-tengberg-current-view-strongminds by Lovisa Tengberg and https://oxpr.io/blog/2017/2/28/konstantin-sietzy-current-view-strongminds by Konstantin Sietzy) that she might look into more

Full list of donations in reverse chronological order (18 donations)

DonorAmount (current USD)Amount rank (out of 18)Donation dateCause areaURLInfluencerNotes
Bill and Melinda Gates Foundation4,802,610.0062017-11-21Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop much needed new treatments for filarial diseases (onchocerciasis and lymphatic filariasis), human African trypanosomiasis and visceral leishmaniasis that are safe, effective, easy-to-use (oral) and affordable..; Aid type: Project-type interventions. Affected regions: Africa.
Bill and Melinda Gates Foundation540,152.00142016-05-09Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop much needed new treatments for filarial diseases (onchocerciasis and lymphatic filariasis), human African trypanosomiasis and visceral leishmaniasis that are safe, effective, easy-to-use (oral) and affordable..; Aid type: Project-type interventions. Affected regions: Africa.
Bill and Melinda Gates Foundation-540,152.00162016-05-09Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support the development of flubendazole as a macrofilaricidal drug candidate for treatment of onchocerciasis loa loa co-infections; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation-1,335,450.00172015-11-11Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to establish and implement new treatment modalities as successful tools to control and support the elimination of Visceral Leishmaniasis in the most endemic regions of South Asia; Aid type: Project-type interventions. Affected regions: South & Central Asia.
Bill and Melinda Gates Foundation59,867,584.0012014-10-24Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop much needed new treatments for filarial diseases (onchocerciasis and lymphatic filariasis), human African trypanosomiasis and visceral leishmaniasis that are safe, effective, easy-to-use (oral) and affordable..; Aid type: Project-type interventions. Affected regions: Africa.
Bill and Melinda Gates Foundation4,398,239.0072014-07-10Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- for clinical development of Oral Fexinidazole for stage 2 Human African Trypanosomiasis; Aid type: Project-type interventions. Affected regions: South of Sahara.
Bill and Melinda Gates Foundation1,000,000.00132014-05-06Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- To foster exploration and innovation needed to identify, develop and deliver the right global health products to those most in need.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation-1,522,143.00182014-04-29Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support the development of flubendazole as a macrofilaricidal drug candidate for treatment of onchocerciasis loa loa co-infections; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Wellcome Trust53,058.00152013-09-16FIXMEhttps://wellcome.ac.uk/sites/default/files/wellcome-grants-awarded-2000-2016.xlsx-- USD 3 Million Awarded to Find Biomarkers for Potential Test of Cure for Chagas Disease. Affected regions: International; affected countries: Switzerland.
Bill and Melinda Gates Foundation2,352,649.0082013-06-26Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to identify new drug candidates for helminths and kinetoplastid diseases. NTD Screening. Investment start date: 11/2/2011 to end date: 3/31/2015. Grantee name: Drugs for Neglected Diseases initiative; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation2,000,000.0092011-11-02Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to identify new drug candidates for helminths and kinetoplastid diseases. NTD Screening. Investment start date: 11/2/2011 to end date: 3/31/2015. Grantee name: Drugs for Neglected Diseases initiative; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Wellcome Trust1,868,635.00102011-07-13FIXMEhttps://wellcome.ac.uk/sites/default/files/wellcome-grants-awarded-2000-2016.xlsx-- USD 3 Million Awarded to Find Biomarkers for Potential Test of Cure for Chagas Disease. Affected regions: International; affected countries: Switzerland.
Bill and Melinda Gates Foundation9,000,000.0042011-06-23Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to establish and implement new treatment modalities as successful tools to control and support the elimination of Visceral Leishmaniasis in the most endemic regions of South Asia; Aid type: Project-type interventions. Affected regions: South & Central Asia.
Bill and Melinda Gates Foundation5,787,659.0052011-04-15Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support the development of flubendazole as a macrofilaricidal drug candidate for treatment of onchocerciasis loa loa co-infections; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Wellcome Trust1,713,553.00112011-01-19FIXMEhttps://wellcome.ac.uk/sites/default/files/wellcome-grants-awarded-2000-2016.xlsx-- Development of E1224 for the treatment of Chagas Disease" to evaluate a promising alternative drug candidate for Chagas disease. Affected regions: International; affected countries: Switzerland.
Bill and Melinda Gates Foundation1,500,000.00122010-06-25Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop new drug candidates for human African trypanosomiasis and visceral leishmaniasis through the pre-clinical stage and ready for an Investigational New Drug filing, and the completion of phase I clinical studies; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation15,000,000.0032009-11-10Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- for clinical development of Oral Fexinidazole for stage 2 Human African Trypanosomiasis; Aid type: Project-type interventions. Affected regions: South of Sahara.
Bill and Melinda Gates Foundation25,729,284.0022007-11-12Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop new drug candidates for human African trypanosomiasis and visceral leishmaniasis through the pre-clinical stage and ready for an Investigational New Drug filing, and the completion of phase I clinical studies; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.